Microdosing Psychedelics to Improve Mood

Phase II randomized, triple-masked crossover trial of low-dose psilocybin (2 mg, oral) administered once weekly for four weeks in a blinded comparison with placebo, followed by a 4-week open-label psilocybin phase.

Primary aim is to assess feasibility, safety and short-term efficacy on depressive symptoms with weekly symptom surveys and follow-up assessments extending up to two years.